Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This purchase was likely arranged some time ago (Aug-Sept-Oct) with the completion of the events where information was available at the time of the agreement, such as Journal publication and filing of lawsuit. It is not coincidental that the purchase was effective at the end of day price of the day the lawsuit was filed. I have done purchase agreements like this before as an insider. It is the difficulty of making these investments that often time prevents insiders of pulling the trigger on buys.
This is not the MM's. This is shorty working overtime.
I highly doubt that would require a share holder vote. That would mean that share holders would have influence on the sales agreement a company makes, which they do not.
The only partnership that makes sense right now with the SP at these levels is an exclusive right to some indications that was granted with an upfront payment, milestone payments and a profit sharing arrangement. There don't have to an equity part of the deal, but there could be an arrangement for future equity purchases.
This is the only thing that would make sense for NWBO, but also the only scenario that would make sense for a BP player.
I think you are 100% correct. This was a DCVax-L webinar and they likely didn’t want to have their sponsored trial included.
Do we know when that 3 months deadline is? Do we have anyone who has the experience and knows if the option for extension is easier than filing a new patent? It does look like the timing is coincidental, though I always believe that timing is almost never coincidental. This is government time, so could be a coincidence.
So in your mind, is it reasonable to assume that there's a high likelihood that the device has passed the compatibility requirements since they have paid for it which is the last step for issuance? That was what my friend and former patent attorney suggested to me. He has been retired for 20+ years and knows nothing about NWBO, so I am not taking his prediction as the ultimate truth.
Only have one post left, so sorry if I don't respond until after 9pm PST
Thanks for your reply. My line of questioning was more in the area of: Can you make changes to a patent after it has been issued? or do you have to file for a new patent? If you have to file for a new patent, would it not make sense to wait with payment/issuance until you were certain that it passed the compatibility requirements of the MHRA so you can make the necessary changes required for the device to pass the compatibility requirements.
I am a former attorney, just not in patent law. I am not saying that paying the issue fee is an indication it works, I am just wondering if they would pay it before the compatibility studies were complete. If it was included in the MIA certification, it would make sense that they waited until the 'all clear' from MHRA before paying. I don't know if they could have made whatever changes to the flaskworks device and made changes to the patent application if the MHRA would have come back with some problems from their inspection. I don't even know if you can makes changes to the device after an issuing of the patent (which is the likely implication of payment) or if you have to file a new patent for the changed device.
I was told by someone way smarter than me (which according to some posters here is quite a few, LOL) that it is a good sign that they paid for the patent either today or yesterday. This person told me that it likely means that this version of Flaskworks has completed the compatibility requirement. I would like for people like Flipper or Henry to chime in or any other patent attorney who might be reading this.
So for those speculating about the massive capping at $1. This is NOT covering. It could be that one shorter is buying the shares another shorter is using to cap it, but it is 100% not a net covering going on. There's likely someone accumulating, but they are not the reason it is at $1, they are just taking advantage of it. Some of the selling could be traders as it has looked different that other days when they were capping. These traders are likely trying to move with the shorts and take advantage of their work. The only problem is that moves have been a lot more expensive without the help of MM's spoofing. Another problem for the shorts with the traders selling (which they need) is that these traders will also buy when price goes down and compete with the shorts trying to cover and move price back up too fast. It's all rather fascinating to watch as compared to before, when the downward moves happened with no real explanation at the time. We now know it was spoofing.
Volume at this time is 3.09M
2.092M at $1
343k at $0.9999
295k at $0.9998
so 2.73M of 3.09M sold at $1, that is 88% of shares sold. That's pretty telling about the capping going on.
They might just have been hoping the price was higher when they did the sale. We all should know that this was not an agreement done on 12/1. At least those of us who have been an insider in a publicly traded company.
Shorts and Market Makers might be hoping that the traders will expect them to close the gap and help with the move down to cover. Otherwise, I don't see that gap closed.
That's not quite true. The MHRA did allow the PIP trial design to be the same as the final SAP for DCVax-L phase III. That would not have happened if they had not felt that the trial design was acceptable for approval. You are somewhat right that we have yet to hear from other 3 RA's, though the FDA has signaled that ECA's is the way forward for these kind of trials.
I am sure they will try the afternoon bear raid. It all depends on how many shares they can find/buy to use. More MM's seem to have jumped in to help OTCN clients short/cap.
In other words: "If we can't spoof, we will just short it to keep the price down and show that the SP would not have been higher.....". I tend to agree, but the capping action is not bringing price down, so counter argument could be that in that case, it would just have stayed around $2 and not gone down. BUT I do think that is partially what is going on. I do think they are careful to not do too much naked/FTD shorting, as that could be discovered in the lawsuit. It's definitely still being manipulated, just more with shorts than MM trading.
IF this insider buy was scheduled months ago, but timed for AFTER the filing of the suit, which they likely have known about for quite some time, it would not preclude the chance of big news. The knowledge at the time of the purchase, if done some time ago, would probably be that they knew the JA would come in the near future, followed by the filing of the law suit. The purchase price of the C-shares looks like was based on the share price on Dec. 1.
I think the news of insider buying is great news. It lines up with my previous thoughts that a partnership this year is highly unlikely. If something like that was happening, Jerry would likely be bared from purchasing if he had any information about this. I do not think it is out of the question, just highly unlikely. NWBO is very top centric in the control of the company, so there's a slight chance that Jerry has not been part of nor has any direct knowledge about any negotiations, but this is unlikely. The deal for his purchase of the C-series shares COULD have been entered into at a much earlier date with the effective date being the day the suit was filed. That would be a way to not trade on insider information, but again unlikely. The poster who said that something has already been signed, might mean a CRL agreement or the MAA application or a BLA submission.
I agree that based on the June presentation, I would not completely eliminate the possibility that Flaskworks could be included. The time it has taken, also leads me to believe there's a chance. We are close to 4 weeks past the median time for MIA approval timeline. As we already had the GMP for the compassionate use manufacturing, I would have assume that the MIA would have been done on the shorter side of the 90 day average MIA cert. That being said, it is probably more likely it is not included.
Day their domain was set to expire, but was renewed last week. Sorry to disappoint.
Let them defend the SP at certain levels on the way up. The 1M shares used to defend at 0.92 are already down $120k. The more shares they use at every level, the more they have to cover when we really start moving on the next news. Unfortunately I see retail traders taking profits at these levels too, but can't blame anyone for taking 10% profit.
Not the first time we see a very friendly relationship between NWBO/Advent and AstraZeneca on social media.
If we can get some data from combo trial, it would be huge. Not sure the SP will be an honest reflection of how huge that would be, but it would solidify the chances of a partnership in 23 and could be big for approval timeline too. If the combo trial show significantly better results than Mucidencel by itself, it would be a great indicator for faster approval and move it to a 100% approval in my mind. I do think we are in the high 90's in term of chance for approval right now.
Won't see any partnership/JV news this year. IMHO. We will see some UK news with MIA and possible MAA application, which should give us a better timeline for UK/EU approval and likely US approval too
I don't necessarily disagree with that sentiment. I am pretty sure, however, that what happened to DNDN and the early problems NWBO faced in the market place, are the reason we have a heavy presence in the UK. LP 'gave' up the US manufacturing and focused on the UK manufacturing support, likely because she felt there would be a lot less resistance in the UK. I find it ironic that the first negative comment on JAMAOnc was from a few UK doctors who have serious conflict of interests, whether that be TTF or radiation conflicts.
Ex. I was asked why I was soft on him in a reply, but his reply included positive statement of the trial, so I wanted to say good on him for changing his tune.
Bio, you've got to relax. Your fear of getting people angry is baseless. You probably would never have filed the lawsuit, as it might anger the MM's.
There's no one saying that what happened to Dendreon will happen to NWBO. What I have said is that there's so many things that they had to deal with, which we have seen in the constant manipulation of both NWBO stock and DCVax-L/Murcidencel. There's so many things that LP have learned from DNDN mess too, that hugely benefit NWBO, such as manufacturing and using multiple RA's for approval. You don't think that these two issues are at the forefront of LP's tactics because of DNDN?
It's a fact that Pazdur was at the advisory panel meeting, without any reason AT ALL to be there. It is a fact that he was mentioned in emails that were obtained through the FOI act with Dr. Martin. It is a fact that these emails were between her and Dr. Scher and were about moving Provenge to another agency within the FDA for the approval decision. It is a fact that Dr. Martin went on to work for a Milken controlled company upon leaving the FDA,
He might have changed his tone due to a horrible event in his private life, but he was instrumental in the delay of approval for Provenge.
He was one of the main reasons Provenge was denied approval in 2007, according to Deep Captive. I hope, like others who were involved back then, he has turned a new leaf and that the many deaths he might have on his conscience (if he has one) has made him see the light. I sure hope that his viewpoints on ECA's are not only meant for easing the approval process for BP, but that he was aware of 'our' trial when his article was written.
I guess this is how you become more powerful in the FDA:
"For now, it merely needs to be emphasized that Pazdur, the FDA official, has unusually close
relationships with Milken and some of his cronies. He was a key player in the ImClone scandal, which
displays remarkable similarities (such as hedge funds in the Milken network betting with great prescience
and insider information mysteriously appearing in The Cancer Letter) to the Dendreon scandal. And with
the apparent encouragement of Dr. Scher and Alison Martin at the National Cancer Institute, Pazdur
appears to have played a key role in derailing Dendreon’s prostate cancer treatment.
Pazdur was not supposed to be the one who decided whether Dendreon’s drug was approved. Instead,
because the drug is a biologic, the decision rested with the FDA’s Center for Biologics Evaluation and
Research (CBER). Nonetheless, Pazdur inserted himself into the decision process. It was at Pazdur’s
behest that Dr. Scher and Dr. Hussain were, despite their ties to competing companies controlled by
Milken’s funds and friends, appointed to the advisory panel that voted on Dendreon’s application."
UK and EU RA's will be the key difference in regard to the final outcome for Murcidence, along with NWBO's focus on manufacturing. Linda Powers have definitely read the Provenge story and have used the shortfalls from Dendreon as the strengths for NWBO. The timing of the lawsuit is absolutely perfect.
I was always dubious about claims that LL was afraid on 5/10, as I have been told she actually did have Covid from a reliable UCLA source. Reading this story about Provenge, I can see how deeply AF could be involved with nefarious people that he would threaten her and making her decide not to do the presentation virtually from the UK. I am not saying this is the case, but I can see it possibly being true.
There's a huge difference between 2007 and 2022, which is one of the reasons I think NWBO will still be a successful investment, even after reading the story of Provenge.
SOCIAL MEDIA AND TECHNOLOGY.
Back then, people supporting Provenge had no way to access the public with the TRUE story, With the popularity of social media, these stories can now come to light and shame the actors involved. Technology has also made it easier to prove the bad acts of people, which should be evident from looking at the facts section of the lawsuit.
Please read the story I linked to. I am not talking about the science at all. Just the web surrounding the bears actions and methods of keeping this drug from saving lives. You might actually see versions of yourself in the story. LOL
I can see why they brought him on when they did. He will likely be a very prominent figure over the next 12 months as a link between NWBO and the DOJ. Without the DOJ or at least the prospects of the DOJ working with NWBO and their lawyers, the lawsuit would not be as damaging to the defendants.
You can find the same arguments in that story like:
"There are better treatments coming in the future". Our UK friends main argument
"The trial will never get approved by FDA" . Our good friends Ex, The Dr and Hygro
A letter written to the FDA by a panelist from their advisory panel, who neglected he had a conflict of interest, which was not true. Our other UK friend Matt Williams, who wrote the comment on the JAMA article.
I am not even referring to the naked short aspect of Dendreon stocks, as I am not convinced that it is the same. It could be now that they might need some naked shorts to keep the price down, but without the options market and with a chance of uplisting on the horizon, this might not be in their current arsenal. The legal shorts might actually wish for uplisting, so they can engage in a more widespread shorting.
There's hundreds of these similarities in this story.
Charities with deep conflict of interests, like the two charities mentioned in a previous post.
Simply an amazing story and a must read for EVERY investor in NWBO. My jaw is still dragging on the floor from the similarities. I wish I would have read this story years ago. I would still have been invested in NWBO, but I would have been trading the stock like crazy. Now with the new lawsuit, that trading part is likely gone.
Reading the story of Provenge is amazing. The arguments from bears are exactly the same as is going on with Murcidencel. If anyone has not yet read the story, I will say it is a must read. Yes it is long and can be a bit confusing because of the 100's of names and characters, but the gist of the story is amazing. Corrupt doctors, journalists and charities. How has this story not been made into a movie? Likely because the government failed to bring those involved to justice, so no real ending to feature. When you read the story, you will find the characters of the story and their arguments are similar to several 'people' you know.
https://www.sec.gov/comments/s7-08-09/s70809-4614.pdf
Thanks QL. What a fascinating story. I agree this is some of what has been going on with NWBO. Obviously some of the people trying to discredit the trial are HF plants. We know a few.
I am not an expert in anything that has to do with science. I have a question to those who know a lot more than me. Do you think that the Direct trial was put on hold because of the fact that NWBO and their scientific advisors thought that it could be approved relatively quick after approval of L, due to the 'platform' nature of the DC Vaccine? I understand that there was a monetary aspect of this as well, as trials are expensive and they decided to focus on L.
If the judge issues something to that effect, minus the limitations of where they can trade which would not be applicable in our case, I would be happy. It's obviously a completely different case, but the monitoring closely of the defendants trades in NWBO with all the tools available would be a good place to start. The added scrutiny can only benefit NWBO.
To begin with, I find it interesting that the shorts seemingly now only use OTCN as their tool to trade. They have probably decided not to use the 7 MM's named in the suit in order to avoid unnecessary oversight.